Repros Receives Positive Feedback From FDA For Male-infertility Drug Candidate – Update
Repros Receives Positive Feedback From FDA For Male-infertility Drug Candidate – Update Monday, Repros Therapeutics Inc. (RPRX) announced that it has received positive feedback from the Food and Drug Administration regarding the fertility preserving indication for its investigational drug Androxal. Tick TockA young gynecology resident, in the midst of her infertility rotation, realizes that she [...]